Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cell-based diagnostic market set to propel to $9bn by 2011

Kalorama Information : 09 January, 2008  (New Product)
A new report released by Kalorama Information states that cell-based diagnostics with applications in haematology, histology, cytology, microbiology, and transplant medicine generated more than $6 billion in revenues last year.
The report indicates that new and innovative enabling technologies are emerging which will propel certain segments of the market forward at double-digit rates.

The new study, Cell-Based Diagnostics: Technologies, Applications, and Markets, 2nd Edition, evaluates the market for both traditional technologies such as haematology, flow cytometry, and traditional stains, as well as increasingly sophisticated molecular techniques and the emerging areas of rare cell event testing, microarrays and beadarrays. These new technologies and digital arrays carry the advantage of being well suited to feed data to software designed to interpret array patterns and create the test result.

These innovations and new methods for genotyping biopsied tissue could revolutionise the treatment of a number of diseases, including: diabetes, cancer, and autoimmune and neurodegenerative diseases and could lead the way to an era of individualised patient therapies using techniques such as microarrays, biochips, PCR and in situ hybridisation.

“The potential for these technologies is huge,” noted Shara Rosen, analyst for Kalorama Information and the author of the study. “In fact, while our current market evaluations are based on commercialised assays and reagents, there is also a vast menu of in-lab developed, or ‘home-brew’ tests using tissue stains, flow reagents, antibodies, molecular probes and dyes marketed by scores of companies, worldwide. As the science of cell diagnostics is perfected, many of these tests are going main stream as authorised test services or market cleared tests.”

Kalorama Information’s 2nd Edition of Cell-Based Diagnostics: Technology, Application and Markets, reviews technologies available and in development from nearly 200 companies and discusses the impact of cell-based diagnostics on patient care, as well as in drug discovery and development research. Analysis of market trends and market forecasts for twelve cell diagnostic segments are also provided.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo